Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Two-State Receptor Model

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...

Depolarizing Blockers: Mechanism of Action

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...

Pharmacodynamic Models: Overview

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Twelve-Month Outcome of Nasolabial Fold Correction by a Novel Non-1,4-Butanediol Diglycidyl Ether, Click-Crosslinked, Long-Chain Hyaluronic Acid Product.

Journal of cosmetic dermatology·2026

Same author

Stoichiometric Antibody-Polymer-Drug Conjugate for Effective Low-Dose Treatment of Breast Cancer.

Biomacromolecules·2025

Same author

Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A).

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

New Parameters Based on Ground Reaction Forces for Monitoring Rehabilitation Following Tibial Fractures and Assessment of Heavily Altered Gait.

Sensors (Basel, Switzerland)·2025

Same author

Author Correction: Structures of synaptic vesicle protein 2A and 2B bound to anticonvulsants.

Nature structural & molecular biology·2025

Same author

Peptide-Purified Anti-N-methyl-D-aspartate Receptor (NMDAR) Autoantibodies Have Inhibitory Effect on Long-Term Synaptic Plasticity.

Pharmaceuticals (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: May 22, 2026

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

Towards a KCC2 blocker pharmacophore model.

Florence Lebon¹, Cécile Pégurier, Marie Ledecq

¹UCB Pharma, UCB NewMedicines, Chemin du Foriest, B-1420 Braine-L'Alleud, Belgium. florence.lebon@ucb.com

Bioorganic & Medicinal Chemistry Letters

|May 22, 2012

Summary

This summary is machine-generated.

Researchers developed the first pharmacophore model for KCC2 blockers using integrated computational and experimental methods. This model aids in designing more effective KCC2 blocker drugs by identifying key molecular features.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Related Experiment Videos

Last Updated: May 22, 2026

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Area of Science:

Medicinal Chemistry
Computational Chemistry
Structural Biology

Background:

The potassium-chloride cotransporter 2 (KCC2) plays a crucial role in neuronal function, and its dysfunction is implicated in various neurological disorders.
Developing targeted KCC2 blockers is a promising therapeutic strategy for conditions like epilepsy and neuropathic pain.
A defined pharmacophore model is essential for guiding the rational design of novel and potent KCC2 inhibitors.

Purpose of the Study:

To establish the first comprehensive pharmacophore model for KCC2 blockers.
To identify common structural and conformational features shared by different series of KCC2 blockers.
To validate the pharmacophore model through the synthesis and testing of improved analogues.

Main Methods:

Integrated multi-disciplinary approach combining physico-chemical studies (XRD, NMR) with molecular modeling.
Structure-Activity Relationship (SAR) analysis of KCC2 blocker analogues.
Synthesis of conformationally constrained analogues to define bioactive conformations.
Comparative analysis of conformational spaces between different KCC2 blocker series.

Main Results:

Identification of a minimal conformational space containing key bioactive conformations for KCC2 blockers.
Determination of common pharmacophoric features shared across distinct KCC2 blocker chemical series.
Successful synthesis of more potent analogues in a second series, confirming the model's predictive power.

Conclusions:

The developed pharmacophore model represents a significant advancement in understanding KCC2 blocker structure-activity relationships.
This model provides a valuable framework for the rational design and optimization of novel KCC2-targeting therapeutics.
The integrated methodology highlights the synergy between computational and experimental techniques in drug discovery.